The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...
(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...
Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...
The 2026 European Society for Medical Oncology (ESMO) Annual Congress held Poster 2279P - ERG-Dependent Prognostic Impact of ...
This was a retrospective, single-center study conducted at a tertiary referral center between 2007 and 2024. Patients who ...
Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...
The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...
This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...
(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...
(UroToday.com) The 2023 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Daniel Petrylak discussing radiographic progression-free survival (rPFS) in patients ...
A total of 25 patients who received ≥2 cycles of toripalimab combined with TIP chemotherapy were enrolled. The objective response rate was 84.0%, with 2 patients achieving complete response and 19 ...
Adaptive MR-guided whole-pelvic SBRT with or without focal intraprostatic lesion boost for high-risk localized prostate Cancer: Adverse events and longitudinal quality-of-life outcomes. November 2, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results